Myelodysplastic Syndrome (MDS)

Lower-Risk
- Intermediate
  - IRB# 16338: Aileron Phase 1/1b ALRN-6924 (Wild Type TP53)
  - IRB# 16964: FORMA phase 1/1b of FT-2102 as single agent and in combination with azacitidine (IDH1 mutation)
  - IRB# 18352: Study coming soon

CMML
- IRB# 18352: Study coming soon

High Risk
- New MDS
  - IRB# 16867: Abbvie 531 phase 1b venetoclax + azacitidine in treatment naïve subjects
  - Studies coming soon: IRB# 18352, IRB# 18809

- Relapsed/Refractory
  - IRB# 16964: FORMA phase 1/1b of FT-2102 as single agent and in combination with azacitidine (IDH1 mutation)
  - IRB# 16964: FORMA phase 1/1b of FT-2102 as single agent and in combination with azacitidine (IDH1 mutation)
  - IRB# 16338: Aileron Phase 1/1b ALRN-6924 (Wild Type TP53)
  - IRB# 17379: Novartis Phase 1B PDR001 and/or MBG453 with decitabine
  - IRB# 16984: Abbvie 522 venetoclax by itself or in combination with azacitidine in relapsed/refractory subjects

- Treatment Related
  - IRB# 15993: HLA-A2.0 and PRAME (relapsed/refractory MDS)

http://www.ohsu.edu/research/rda/so/knight.php